company background image
2I9 logo

Karolinska Development DB:2I9 Stock Report

Last Price

€0.12

Market Cap

€35.8m

7D

4.4%

1Y

-21.7%

Updated

27 Mar, 2024

Data

Company Financials +

Karolinska Development AB (publ)

DB:2I9 Stock Report

Market Cap: €35.8m

2I9 Stock Overview

Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies.

2I9 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends0/6

Karolinska Development AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Karolinska Development
Historical stock prices
Current Share Pricekr0.12
52 Week Highkr0.17
52 Week Lowkr0.098
Beta0.39
1 Month Change-5.17%
3 Month Change-10.93%
1 Year Change-21.73%
3 Year Change-16.14%
5 Year Change-78.34%
Change since IPO-85.47%

Recent News & Updates

Recent updates

Shareholder Returns

2I9DE PharmaceuticalsDE Market
7D4.4%2.3%1.9%
1Y-21.7%-25.9%7.3%

Return vs Industry: 2I9 exceeded the German Pharmaceuticals industry which returned -25.9% over the past year.

Return vs Market: 2I9 underperformed the German Market which returned 7.3% over the past year.

Price Volatility

Is 2I9's price volatile compared to industry and market?
2I9 volatility
2I9 Average Weekly Movement9.2%
Pharmaceuticals Industry Average Movement6.3%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 2I9 has not had significant price volatility in the past 3 months.

Volatility Over Time: 2I9's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
20038Viktor Drvotahttps://www.karolinskadevelopment.com

Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark.

Karolinska Development AB (publ) Fundamentals Summary

How do Karolinska Development's earnings and revenue compare to its market cap?
2I9 fundamental statistics
Market cap€35.77m
Earnings (TTM)€468.46k
Revenue (TTM)€175.17k

76.4x

P/E Ratio

204.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2I9 income statement (TTM)
Revenuekr2.01m
Cost of Revenuekr0
Gross Profitkr2.01m
Other Expenses-kr3.37m
Earningskr5.39m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 26, 2024

Earnings per share (EPS)0.02
Gross Margin100.00%
Net Profit Margin267.43%
Debt/Equity Ratio0%

How did 2I9 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.